AstraZeneca starts manufacturing drug targeting cancer cells in Kaluga

AstraZeneca starts manufacturing drug targeting cancer cells in Kaluga September 14, 2017, 12:42

AstraZeneca, an international biopharmaceutical company, launched a new high-tech manufacturing process at its plant in Vorsino industrial park of Kaluga region. One of the first medicines to be produced on a new line will be osimertinib, an innovative targeted agent for the treatment of lung cancer.

The opening of the new production line will allow to manufacture not only osimertinib, but also one drug for the treatment of cardiovascular diseases, one drug for the treatment of type 2 diabetes, and another oncological drug for the treatment of lung cancer. The total output will be up to 3.5 million packages of innovative AstraZeneca medicines a year. According to the current schedule of localization, the manufacturing is expected to reach full cycle in 2020.

AstraZeneca plant produces more than 30 innovative drugs for the treatment of diseases in such therapeutic areas as oncology, cardiology, gastroenterology, psychiatry, and pulmonology. This represents almost 80% of the company’s portfolio in Russia.

https://gmpnews.net/2017/09/astrazeneca-starts-manufacturing-drug-targeting-cancer-cells-in-kaluga/

cancer

or on to add a comment to scientific problem you are interested in!

Comments (0)

You may also be interested in

Personalized melanoma vaccines marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The tailor-made vaccines, given to three patients with advanced melanoma, appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors. The finding is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer. The research is reported April 2 in Science Express, in a special issue devoted to cancer immunology and immunotherapy.